Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keriann M. Backus is active.

Publication


Featured researches published by Keriann M. Backus.


Nature | 2016

Proteome-wide covalent ligand discovery in native biological systems

Keriann M. Backus; Bruno E. Correia; Kenneth M. Lum; Stefano Forli; Benjamin D. Horning; Gonzalo E. González-Páez; Sandip Chatterjee; Bryan R. Lanning; John R. Teijaro; Arthur J. Olson; Dennis W. Wolan; Benjamin F. Cravatt

Small molecules are powerful tools for investigating protein function and can serve as leads for new therapeutics. Most human proteins, however, lack small-molecule ligands, and entire protein classes are considered ‘undruggable’. Fragment-based ligand discovery can identify small-molecule probes for proteins that have proven difficult to target using high-throughput screening of complex compound libraries. Although reversibly binding ligands are commonly pursued, covalent fragments provide an alternative route to small-molecule probes, including those that can access regions of proteins that are difficult to target through binding affinity alone. Here we report a quantitative analysis of cysteine-reactive small-molecule fragments screened against thousands of proteins in human proteomes and cells. Covalent ligands were identified for >700 cysteines found in both druggable proteins and proteins deficient in chemical probes, including transcription factors, adaptor/scaffolding proteins, and uncharacterized proteins. Among the atypical ligand–protein interactions discovered were compounds that react preferentially with pro- (inactive) caspases. We used these ligands to distinguish extrinsic apoptosis pathways in human cell lines versus primary human T cells, showing that the former is largely mediated by caspase-8 while the latter depends on both caspase-8 and -10. Fragment-based covalent ligand discovery provides a greatly expanded portrait of the ligandable proteome and furnishes compounds that can illuminate protein functions in native biological systems.


Nature Chemical Biology | 2011

Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis

Keriann M. Backus; Helena I. Boshoff; Conor S. Barry; Omar Boutureira; Mitul K. Patel; François D'Hooge; Seung Seo Lee; Laura E. Via; Kapil Tahlan; Clifton E. Barry; Benjamin G. Davis

The detection of tuberculosis currently relies upon insensitive and unspecific techniques; newer diagnostics would ideally co-opt specific bacterial processes to provide real-time readouts. The trehalose mycolyltransesterase enzymes (antigens 85A, 85B and 85C (Ag85A, Ag85B, Ag85C)) serve as essential mediators of cell envelope function and biogenesis in Mycobacterium tuberculosis. Through the construction of a systematically varied sugar library, we show here that Ag85 enzymes have exceptionally broad substrate specificity. This allowed exogenously added synthetic probes to be specifically incorporated into M. tuberculosis growing in vitro and within macrophages. Even bulky substituents, such as a fluorescein-containing trehalose probe (FITC-trehalose), were incorporated by growing bacilli, thereby producing fluorescent bacteria; microscopy revealed selective labeling of poles and membrane. Addition of FITC-trehalose to M. tuberculosis-infected macrophages allowed selective, sensitive detection of M. tuberculosis within infected mammalian macrophages. These studies suggest that analogs of trehalose may prove useful as probes of function and for other imaging modalities.


Cell | 2017

Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases

Chun-Jun Guo; Fang-Yuan Chang; Thomas P. Wyche; Keriann M. Backus; Timothy M. Acker; Masanori Funabashi; Mao Taketani; Mohamed S. Donia; Stephen Nayfach; Katherine S. Pollard; Charles S. Craik; Benjamin F. Cravatt; Jon Clardy; Christopher A. Voigt; Michael A. Fischbach

The gut microbiota modulate host biology in numerous ways, but little is known about the molecular mediators of these interactions. Previously, we found a widely distributed family of nonribosomal peptide synthetase gene clusters in gut bacteria. Here, by expressing a subset of these clusters in Escherichia coli or Bacillus subtilis, we show that they encode pyrazinones and dihydropyrazinones. At least one of the 47 clusters is present in 88% of the National Institutes of Health Human Microbiome Project (NIH HMP) stool samples, and they are transcribed under conditions of host colonization. We present evidence that the active form of these molecules is the initially released peptide aldehyde, which bears potent protease inhibitory activity and selectively targets a subset of cathepsins in human cell proteomes. Our findings show that an approach combining bioinformatics, synthetic biology, and heterologous gene cluster expression can rapidly expand our knowledge of the metabolic potential of the microbiota while avoiding the challenges of cultivating fastidious commensals.


Science Signaling | 2016

Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells

Megan M. Blewett; Jiji Xie; Balyn W. Zaro; Keriann M. Backus; Amnon Altman; John R. Teijaro; Benjamin F. Cravatt

Chemical proteomics analysis suggests the mechanism of action of a drug used to treat autoimmune diseases. Uncovering how a drug works The drug dimethyl fumarate (DMF), which is used to treat autoimmune diseases, including psoriasis and multiple sclerosis, may act by modifying cysteine residues in proteins. A better understanding of its mechanism of action and target proteins is required because it can cause life-threatening infections in some patients. Blewett et al. used a chemical proteomics approach to identify cysteine residues in human T cell proteins that reacted with DMF. One such target, the kinase PKCθ, contains two cysteine residues that were targeted by DMF, which prevented PKCθ from interacting with the T cell costimulatory receptor CD28 and mediating full T cell activation. This approach should aid in developing similar drugs with fewer side effects. Dimethyl fumarate (DMF) is an electrophilic drug that is used to treat autoimmune conditions, including multiple sclerosis and psoriasis. The mechanism of action of DMF is unclear but may involve the covalent modification of proteins or DMF serving as a prodrug that is converted to monomethyl fumarate (MMF). We found that DMF, but not MMF, blocked the activation of primary human and mouse T cells. Using a quantitative, site-specific chemical proteomic platform, we determined the DMF sensitivity of >2400 cysteine residues in human T cells. Cysteines sensitive to DMF, but not MMF, were identified in several proteins with established biochemical or genetic links to T cell function, including protein kinase Cθ (PKCθ). DMF blocked the association of PKCθ with the costimulatory receptor CD28 by perturbing a CXXC motif in the C2 domain of this kinase. Mutation of these DMF-sensitive cysteines also impaired PKCθ-CD28 interactions and T cell activation, designating the C2 domain of PKCθ as a key functional, electrophile-sensing module important for T cell biology.


Nature Chemistry | 2017

Global profiling of lysine reactivity and ligandability in the human proteome

Stephan M. Hacker; Keriann M. Backus; Michael R. Lazear; Stefano Forli; Bruno E. Correia; Benjamin F. Cravatt

Nucleophilic amino acids make important contributions to protein function, including performing key roles in catalysis and serving as sites for post-translational modification. Electrophilic groups that target amino-acid nucleophiles have been used to create covalent ligands and drugs, but have, so far, been mainly limited to cysteine and serine. Here, we report a chemical proteomic platform for the global and quantitative analysis of lysine residues in native biological systems. We have quantified, in total, more than 9,000 lysines in human cell proteomes and have identified several hundred residues with heightened reactivity that are enriched at protein functional sites and can frequently be targeted by electrophilic small molecules. We have also discovered lysine-reactive fragment electrophiles that inhibit enzymes by active site and allosteric mechanisms, as well as disrupt protein-protein interactions in transcriptional regulatory complexes, emphasizing the broad potential and diverse functional consequences of liganding lysine residues throughout the human proteome.


Journal of the American Chemical Society | 2011

ESI-MS assay of M. tuberculosis cell wall antigen 85 enzymes permits substrate profiling and design of a mechanism-based inhibitor.

Conor S. Barry; Keriann M. Backus; Barry Ce rd; Benjamin G. Davis

Mycobacterium tuberculosis Antigen 85 enzymes are vital to the integrity of the highly impermeable cell envelope and are potential therapeutic targets. Kinetic analysis using a label-free assay revealed both mechanistic details and a substrate profile that allowed the design and construction of a selective in vitro mechanism-based inhibitor.


Cell | 2017

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Liron Bar-Peled; Esther Kemper; Radu M. Suciu; Ekaterina V. Vinogradova; Keriann M. Backus; Benjamin D. Horning; Thomas A. Paul; Taka-Aki Ichu; Robert U. Svensson; Jose Olucha; Max W. Chang; Bernard P. Kok; Zhou Zhu; Nathan T. Ihle; Melissa M. Dix; Ping Jiang; Matthew Merrill Hayward; Enrique Saez; Reuben J. Shaw; Benjamin F. Cravatt

The transcription factor NRF2 is a master regulator of the cellular antioxidant response, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutations in the negative regulator KEAP1. While direct pharmacological inhibition of NRF2 has proven challenging, its aberrant activation rewires biochemical networks in cancer cells that may create special vulnerabilities. Here, we use chemical proteomics to map druggable proteins that are selectively expressed in KEAP1-mutant NSCLC cells. Principal among these is NR0B1, an atypical orphan nuclear receptor that we show engages in a multimeric protein complex to regulate the transcriptional output of KEAP1-mutant NSCLC cells. We further identify small molecules that covalently target a conserved cysteine within the NR0B1 protein interaction domain, and we demonstrate that these compounds disrupt NR0B1 complexes and impair the anchorage-independent growth of KEAP1-mutant cancer cells. Our findings designate NR0B1 as a druggable transcriptional regulator that supports NRF2-dependent lung cancers.


Journal of Biological Chemistry | 2014

The Three Mycobacterium tuberculosis Antigen 85 Isoforms Have Unique Substrates and Activities Determined by Non-active Site Regions

Keriann M. Backus; Michael A. Dolan; Conor S. Barry; Maju Joe; Peter McPhie; Helena I. Boshoff; Todd L. Lowary; Benjamin G. Davis; Clifton E. Barry

Background: The existence of three antigen 85 isoforms in Mycobacterium tuberculosis has been proposed to be due to immune evasion. Results: Mutating divergent amino acids from outside the enzyme active site changes enzyme activity and substrate preference. Conclusion: These enzymes have unique substrate preferences and are regulated by a second carbohydrate-binding site. Significance: Understanding the enzymatic function of these enzymes may provide novel chemotherapeutic strategies. The three isoforms of antigen 85 (A, B, and C) are the most abundant secreted mycobacterial proteins and catalyze transesterification reactions that synthesize mycolated arabinogalactan, trehalose monomycolate (TMM), and trehalose dimycolate (TDM), important constituents of the outermost layer of the cellular envelope of Mycobacterium tuberculosis. These three enzymes are nearly identical at the active site and have therefore been postulated to exist to evade host immunity. Distal to the active site is a second putative carbohydrate-binding site of lower homology. Mutagenesis of the three isoforms at this second site affected both substrate selectivity and overall catalytic activity in vitro. Using synthetic and natural substrates, we show that these three enzymes exhibit unique selectivity; antigen 85A more efficiently mycolates TMM to form TDM, whereas C (and to a lesser extent B) has a higher rate of activity using free trehalose to form TMM. This difference in substrate selectivity extends to the hexasaccharide fragment of cell wall arabinan. Mutation of secondary site residues from the most active isoform (C) into those present in A or B partially interconverts this substrate selectivity. These experiments in combination with molecular dynamics simulations reveal that differences in the N-terminal helix α9, the adjacent Pro216–Phe228 loop, and helix α5 are the likely cause of changes in activity and substrate selectivity. These differences explain the existence of three isoforms and will allow for future work in developing inhibitors.


Journal of the American Chemical Society | 2017

Covalent Modulators of the Vacuolar ATPase

Ying-Chu Chen; Keriann M. Backus; Maria Merkulova; Christina Yang; Dennis Brown; Benjamin F. Cravatt; Chao Zhang

The vacuolar H+ ATPase (V-ATPase) is a complex multisubunit machine that regulates important cellular processes through controlling acidity of intracellular compartments in eukaryotes. Existing small-molecule modulators of V-ATPase either are restricted to targeting one membranous subunit of V-ATPase or have poorly understood mechanisms of action. Small molecules with novel and defined mechanisms of inhibition are thus needed to functionally characterize V-ATPase and to fully evaluate the therapeutic relevance of V-ATPase in human diseases. We have discovered electrophilic quinazolines that covalently modify a soluble catalytic subunit of V-ATPase with high potency and exquisite proteomic selectivity as revealed by fluorescence imaging and chemical proteomic activity-based profiling. The site of covalent modification was mapped to a cysteine residue located in a region of V-ATPase subunit A that is thought to regulate the dissociation of V-ATPase. We further demonstrate that a previously reported V-ATPase inhibitor, 3-bromopyruvate, also targets the same cysteine residue and that our electrophilic quinazolines modulate the function of V-ATPase in cells. With their well-defined mechanism of action and high proteomic specificity, the described quinazolines offer a powerful set of chemical probes to investigate the physiological and pathological roles of V-ATPase.


Reference Module in Chemistry, Molecular Sciences and Chemical Engineering#R##N#Comprehensive Natural Products II#R##N#Chemistry and Biology | 2010

Mycolic Acid/Cyclopropane Fatty Acid/Fatty Acid Biosynthesis and Health Relations

David B. Kastrinsky; Nicholas S. McBride; Keriann M. Backus; Jason J. LeBlanc; Clifton E. Barry

One of the most exciting fronts in research into infectious diseases in the current ‘genomic’ era is our expanding understanding of the chemical biology of the interaction of pathogens and their hosts. Much like their protein and nucleic acids counterparts, bacterial lipids and glycolipids are subject to evolutionary pressures that result in differential structure, variable expression levels, and differential ability of the host to recognize and respond to these factors. The pathogenesis of tuberculosis and related mycobacterial diseases is defining the leading edge of this emergent field and this chapter explores the structures, biosynthesis, and biological function of the diverse natural products that mediate human interactions with mycobacteria.

Collaboration


Dive into the Keriann M. Backus's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clifton E. Barry

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

John R. Teijaro

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Helena I. Boshoff

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenneth M. Lum

Scripps Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge